Skip to main content

Advertisement

SpringerLink
Log in

Chemotherapy-Associated Hepatotoxicity and Hepatic Resection for Metastatic Colorectal Cancer

  • Colorectal Cancer Hepatic Metastases (MA Choti, Section Editor)
  • Published:
Current Colorectal Cancer Reports

Abstract

Approximately 50 % of patients with colorectal cancer will develop liver metastases. Complete resection is associated with 50 % five-year overall survival and 20 % long-term cure. Use of preoperative chemotherapy for patients with resectable colorectal metastasis to the liver is controversial. Among the arguments against use of preoperative chemotherapy is the resulting hepatotoxicity, which may increase the risk of hepatectomy. In this review, we assess the liver-specific toxicity profiles of the most commonly used chemotherapy agents and how this toxicity affects perioperative outcomes. We also comment on the use of neoadjuvant chemotherapy for patients with resectable colorectal metastasis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30.

    Article  PubMed  Google Scholar 

  2. Stangl R, Altendorf-Hofmann A, Charnley RM, Scheele J. Factors influencing the natural history of colorectal liver metastases. Lancet. 1994;343(8910):1405–10.

    Article  CAS  PubMed  Google Scholar 

  3. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230(3):309–18. discussion318–21.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. Tomlinson JS, Jarnagin WR, DeMatteo RP, Fong Y, Kornprat P, Gönen M, et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol Am Soc Clin Oncol. 2007;25(29):4575–80.

    Article  Google Scholar 

  5. Rees M, Tekkis PP, Welsh FKS, O’Rourke T, John TG. Evaluation of Long-term Survival After Hepatic Resection for Metastatic Colorectal Cancer. Ann Surg. 2008;247(1):125–35.

    Article  PubMed  Google Scholar 

  6. Viganò L, Ferrero A, Tesoriere Lo R, Capussotti L. Liver surgery for colorectal metastases: results after 10 years of follow-up. Long-term survivors, late recurrences, and prognostic role of morbidity. Ann Surg Oncol. Springer-Verlag; 2008; 15(9):2458–64.

    Google Scholar 

  7. de Gramont A, Bosset JF, Milan C, Rougier P, Bouche O, Etienne PL, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol. 1997;15(2):808–15.

    PubMed  Google Scholar 

  8. Pestalozzi BC. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med. 2001;344(4). authorreply306–7.

    Google Scholar 

  9. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335–42.

    Article  CAS  PubMed  Google Scholar 

  10. Van Cutsem E, Köhne C-H, Hitre E, Zaluski J, Chang Chien C-R, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360(14):1408–17.

    Article  PubMed  Google Scholar 

  11. House Mg, Ito H, Gönen M, Fong Y, Allen PJ, DeMatteo RP, et al. Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution. Journal of the American College of Surgeons. 2010; 210(5):744–52–752–5.

  12. Shindoh J, Vauthey JN, Zimmitti G, Curley SA, Huang SY, Mahvash A, et al. Analysis of the efficacy of portal vein embolization for patients with extensive liver malignancy and very low future liver remnant volume, including a comparison with the associating liver partition with portal vein ligation for staged hepatectomy approach. J Am Coll Surg. 2013;217(1):126–33. discussion133–4.

    Article  PubMed  Google Scholar 

  13. Cauchy F, Aussilhou B, Dokmak S, Fuks D, Gaujoux S, Farges O, et al. Reappraisal of the Risks and Benefits of Major Liver Resection in Patients With Initially Unresectable Colorectal Liver Metastases. Ann Surg. 2012;256(5):746–54. A report of outcomes for 87 patients who received extended chemotherapy before liver resection. Patients who had long-term treatment, defined as 12 or more cycles of chemotherapy, had significantly worse postoperative mortality and major morbidity. This reveals the potential detrimental effects of long courses of neoadjuvant chemotherapy.

    Article  PubMed  Google Scholar 

  14. Carpizo DR, Are C, Jarnagin W, DeMatteo R, Fong Y, Gönen M, et al. Liver Resection for Metastatic Colorectal Cancer in Patients with Concurrent Extrahepatic Disease: Results in 127 Patients Treated at a Single Center. Ann Surg Oncol. 2009;16(8):2138–46.

    Article  PubMed  Google Scholar 

  15. Nordlinger B, Guiguet M, Vaillant JC, Balladur P, Boudjema K, Bachellier P, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Française de Chirurgie. Cancer. 1996;77(7):1254–62.

    Article  CAS  PubMed  Google Scholar 

  16. Poon MA, O'Connell MJ, Moertel CG, Wieand HS, Cullinan SA, Everson LK, et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol. 1989;7(10):1407–18.

    CAS  PubMed  Google Scholar 

  17. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18(16):2938–47.

    PubMed  Google Scholar 

  18. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000;355(9209):1041–7.

    Article  CAS  PubMed  Google Scholar 

  19. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000;343(13):905–14.

    Article  CAS  PubMed  Google Scholar 

  20. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study. J Clin Oncol. 2008;26(12):2013–9.

    Article  CAS  PubMed  Google Scholar 

  21. Scheithauer W, Rosen H, Kornek GV, Sebesta C, Depisch D. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ. 1993;306(6880):752–5.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  22. Mitry E, Fields ALA, Bleiberg H, Labianca R, Portier G, Tu D, et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol Am Soc Clin Oncol. 2008;26(30):4906–11.

    Article  CAS  Google Scholar 

  23. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008;371(9617):1007–16.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  24. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2013;14(12):1208–15. Long-term follow-up of the EORTC 40983 study, a phase III randomized controlled trial comparing perioperative FOLFOX therapy with surgery alone for patients with resectable CRLM. In the initial report from 2008, Nordlinger reported a 7.3 % improvement in three-year progression-free survival with use of perioperative FOLFOX (P = 0.058). In this article, the median follow-up is 8.5 years and there is no difference in overall survival between the two groups.

    Article  CAS  PubMed  Google Scholar 

  25. Ychou M, Raoul JL, Douillard JY, Gourgou-Bourgade S, Bugat R, Mineur L, et al. A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). Ann Oncol. 2009;20(4):674–80.

    Article  CAS  PubMed  Google Scholar 

  26. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. Wiley Subscription Services, Inc., A Wiley Company; 2005; 41(6):1313–21.

  27. Kooby DA, Fong Y, Suriawinata A, Gönen M, Allen PJ, Klimstra DS, et al. Impact of steatosis on perioperative outcome following hepatic resection. J Gastrointest Surg. 2003;7(8):1034–44.

    Article  PubMed  Google Scholar 

  28. McCormack L, Petrowsky H, Jochum W, Furrer K, Clavien P-A. Hepatic steatosis is a risk factor for postoperative complications after major hepatectomy: a matched case-control study. Ann Surg. 2007;245(6):923–30.

    Article  PubMed Central  PubMed  Google Scholar 

  29. de Meijer VE, Kalish BT, Puder M, Ijzermans JNM. Systematic review and meta-analysis of steatosis as a risk factor in major hepatic resection. Br J Surg. John Wiley & Sons, Ltd; 2010: 97(9):1331–9.

    Google Scholar 

  30. Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med. 2005;143(10):722–8.

    Article  CAS  PubMed  Google Scholar 

  31. Bower M, Wunderlich C, Brown R, Scoggins CR, McMasters KM, Martin RCG. Obesity rather than neoadjuvant chemotherapy predicts steatohepatitis in patients with colorectal metastasis. Am J Surg. 2013;205(6):685–90. A report of 208 patients who underwent hepatic resection for CRLM. Obesity was the strongest predictor of steatosis and steatohepatitis, irrespective of use of neoadjuvant chemotherapy.

    Article  PubMed  Google Scholar 

  32. Pilgrim CHC, Satgunaseelan L, Pham A, Murray W, Link E, Smith M, et al. Correlations between histopathological diagnosis of chemotherapy-induced hepatic injury, clinical features, and perioperative morbidity. HPB. 2012;14(5):333–40.

    Article  PubMed Central  PubMed  Google Scholar 

  33. DeLeve LD, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis. 2002;22(1):27–42.

    Article  PubMed  Google Scholar 

  34. Rubbia-Brandt L, Audard V, Sartoretti P, Roth AD, Brezault C, Le Charpentier M, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol. 2004;15(3):460–6.

    Article  CAS  PubMed  Google Scholar 

  35. Wicherts DA, de Haas RJ, Sebagh M, Ciacio O, Lévi F, Paule B, et al. Regenerative nodular hyperplasia of the liver related to chemotherapy: impact on outcome of liver surgery for colorectal metastases. Ann Surg Oncol. Springer-Verlag; 2011; 18(3):659–69.

    Google Scholar 

  36. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA. Hepatic toxicity associated with fluorouracil plus levamisole adjuvant therapy. J Clin Oncol. 1993;11(12):2386–90.

    CAS  PubMed  Google Scholar 

  37. Hwang PM, Bunz F, Yu J, Rago C, Chan TA, Murphy MP, et al. Ferredoxin reductase affects p53-dependent, 5-fluorouracil-induced apoptosis in colorectal cancer cells. Nat Med. 2001;7(10):1111–7.

    Article  CAS  PubMed  Google Scholar 

  38. Zeiss J, Merrick HW, Savolaine ER, Woldenberg LS, Kim K, Schlembach PJ. Fatty liver change as a result of hepatic artery infusion chemotherapy. Am J Clin Oncol. 1990;13(2):156–60.

    Article  CAS  PubMed  Google Scholar 

  39. Peppercorn PD, Reznek RH, Wilson P, Slevin ML, Gupta RK. Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer. Br J Cancer. 1998;77(11):2008–11.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  40. Cercek A, D’Angelica M, Power D, Capanu M, Gewirtz A, Patel D, et al. Floxuridine Hepatic Arterial Infusion Associated Biliary Toxicity Is Increased by Concurrent Administration of Systemic Bevacizumab. Ann Surg Oncol. Springer US; 2013; 21(2):479–86. Summary of three prospective trials of HAI FUDR with or without systemic bevacizumab chemotherapy. Addition of bevacizumab significantly increased biliary toxicity. Ten of 80 patients (12.5 %) who received systemic bevacizumab required biliary stenting, as compared with none of the 121 patients who received HAI therapy alone.

  41. Woynarowski JM, Chapman WG, Napier C, Herzig MC, Juniewicz P. Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA. Mol Pharmacol. 1998;54(5):770–7.

    CAS  PubMed  Google Scholar 

  42. Tisman G, MacDonald D, Shindell N, Reece E, Patel P, Honda N, et al. Oxaliplatin toxicity masquerading as recurrent colon cancer. J Clin Oncol. 2004;22(15):3202–4.

    Article  PubMed  Google Scholar 

  43. Laurent A, Nicco C, Chéreau C, Goulvestre C, Alexandre J, Alves A, et al. Controlling tumor growth by modulating endogenous production of reactive oxygen species. Cancer Res. 2005;65(3):948–56.

    CAS  PubMed  Google Scholar 

  44. Vauthey J-N, Pawlik TM, Ribero D, Wu T-T, Zorzi D, Hoff PM, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol Am Soc Clin Oncol. 2006;24(13):2065–72.

    Article  CAS  Google Scholar 

  45. Aloia T, Sebagh M, Plasse M, Karam V, Lévi F, Giacchetti S, et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol Am Soc Clin Oncol. 2006;24(31):4983–90.

    Article  CAS  Google Scholar 

  46. Nakano H, Oussoultzoglou E, Rosso E, Casnedi S, Chenard-Neu M-P, Dufour P, et al. Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg. 2008;247(1):118–24.

    Article  PubMed  Google Scholar 

  47. Viganò L, Capussotti L, De Rosa G, De Saussure WO, Mentha G, Rubbia-Brandt L. Liver resection for colorectal metastases after chemotherapy: impact of chemotherapy-related liver injuries, pathological tumor response, and micrometastases on long-term survival. Ann Surg. 2013;258(5):731–40. Discussion741–2. Report of 323 patients who received neoadjuvant oxaliplatin or irinotecan-based chemotherapy. The authors noted increased SOS in oxaliplatin-treated patients compared with the irinotecan-treated cohort. In contrast with Vauthey [44], they did not find an association between irinotecan and steatohepatitis. The presence of chemotherapy-associated liver injuries did not affect long-term survival.

    Article  PubMed  Google Scholar 

  48. Wolf PS, Park JO, Bao F, Allen PJ, DeMatteo RP, Fong Y, et al. Preoperative chemotherapy and the risk of hepatotoxicity and morbidity after liver resection for metastatic colorectal cancer: a single institution experience. J Am Coll Surg. 2013;216(1):41–9. Report of 506 patients who underwent hepatic resection for CRLM from 2003–2007. Two-hundred and fifty patients received neoadjuvant chemotherapy. Although they found a significant association between irinotecan use and steatohepatitis, there was no 90-day operative mortality among patients who had steatohepatitis. This is in contrast with Vauthey’s experience, where irinotecan-induced steatohepatitis significantly increased the risk of post-hepatectomy mortality [44]. In addition, they found no association between SOS and oxaliplatin use or between chemotherapy and postoperative complication, which is also in contrast with other reports.

    Article  PubMed  Google Scholar 

  49. Tamandl D, Klinger M, Eipeldauer S, Herberger B, Kaczirek K, Gruenberger B, et al. Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy. Ann Surg Oncol. Springer-Verlag; 2011; 18(2):421–30.

    Google Scholar 

  50. Shimamatsu K, Wanless IR. Role of ischemia in causing apoptosis, atrophy, and nodular hyperplasia in human liver. Hepatology. Wiley Subscription Services, Inc., A Wiley Company; 1997; 26(2):343–50.

  51. Hubert C, Sempoux C, Horsmans Y, Rahier J, Humblet Y, Machiels JP, et al. Nodular regenerative hyperplasia: a deleterious consequence of chemotherapy for colorectal liver metastases? Liver Int. Blackwell Publishing Ltd; 2007; 27(7):938–43.

  52. van den Broek MAJ, Olde Damink SWM, Driessen A, Dejong CHC, Bemelmans MHA. Nodular regenerative hyperplasia secondary to neoadjuvant chemotherapy for colorectal liver metastases. Case Rep Med. Hindawi Publishing Corporation; 2009; 2009(1):457975–4.

  53. Morris-Stiff G, White AD, Gomez D, CAMERON IC, Farid S, Toogood GJ, et al. Nodular regenerative hyperplasia (NRH) complicating oxaliplatin chemotherapy in patients undergoing resection of colorectal liver metastases. Eur J Surg Oncol. 2013.

  54. Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res. 2001;7(8):2182–94.

    CAS  PubMed  Google Scholar 

  55. Fulco RA, Costa C, Germanò MP, Torre EA, Viscomi MG, Salimbeni V, et al. Hepatotoxicity of camptothecin derivatives in a primary culture system of rat hepatocytes. J Chemother. 2000;12(4):345–51.

    Article  CAS  PubMed  Google Scholar 

  56. Fernandez FG, Ritter J, Goodwin JW, Linehan DC, Hawkins WG, Strasberg SM. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg. 2005;200(6):845–53.

    Article  PubMed  Google Scholar 

  57. Pawlik TM, Olino K, Gleisner AL, Torbenson M, Schulick R, Choti MA. Preoperative chemotherapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome. J Gastrointest Surg. 2007;11(7):860–8.

    Article  PubMed  Google Scholar 

  58. Ribero D, Wang H, Donadon M, Zorzi D, Thomas MB, Eng C, et al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer. Wiley Subscription Services, Inc., A Wiley Company; 2007; 110(12):2761–7.

  59. Klinger M, Eipeldauer S, Hacker S, Herberger B, Tamandl D, Dorfmeister M, et al. Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases. Eur J Surg Oncol. 2009;35(5):515–20.

    Article  CAS  PubMed  Google Scholar 

  60. D’Angelica M, Kornprat P, Gönen M, Chung K-Y, Jarnagin WR, DeMatteo RP, et al. Lack of Evidence for Increased Operative Morbidity After Hepatectomy with Perioperative Use of Bevacizumab: A Matched Case-Control Study. Ann Surg Oncol. Springer-Verlag; 2006; 14(2):759–65.

    Google Scholar 

  61. Gruenberger B, Tamandl D, Schueller J, Scheithauer W, Zielinski C, Herbst F, et al. Bevacizumab, Capecitabine, and Oxaliplatin As Neoadjuvant Therapy for Patients With Potentially Curable Metastatic Colorectal Cancer. J Clin Oncol. 2008;26(11):1830–5.

    Article  CAS  PubMed  Google Scholar 

  62. Pessaux P, Marzano E, Casnedi S, Bachellier P, Jaeck D, Chenard MP. Histological and immediate postoperative outcome after preoperative cetuximab: case-matched control study. World J Surg. Springer-Verlag; 2010; 34(11):2765–72.

    Google Scholar 

  63. Adam R, Aloia T, Lévi F, Wicherts DA, de Haas RJ, Paule B, et al. Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. J Clin Oncol Am Soc Clin Oncol. 2007;25(29):4593–602.

    Article  CAS  Google Scholar 

  64. Karoui M, Penna C, Amin-Hashem M, Mitry E, Benoist S, Franc B, et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg. 2006;243(1):1–7.

    Article  PubMed Central  PubMed  Google Scholar 

  65. Scoggins CR, Campbell ML, Landry CS, Slomiany BA, Woodall CE, McMasters KM, et al. Preoperative Chemotherapy Does Not Increase Morbidity or Mortality of Hepatic Resection for Colorectal Cancer Metastases. Ann Surg Oncol. 2008;16(1):35–41.

    Article  PubMed  Google Scholar 

  66. Allen PJ, Kemeny N, Jarnagin W, DeMatteo R, Blumgart L, Fong Y. Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases. J Gastrointest Surg. 2003;7(1):109–15. discussion116–7.

    Article  PubMed  Google Scholar 

  67. Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg. 2004;240(4):644–57. discussion657–8.

    PubMed Central  PubMed  Google Scholar 

  68. Gallagher DJ, Zheng J, Capanu M, Haviland D, Paty P, Dematteo RP, et al. Response to Neoadjuvant Chemotherapy Does Not Predict Overall Survival for Patients With Synchronous Colorectal Hepatic Metastases. Ann Surg Oncol. 2009;16(7):1844–51.

    Article  PubMed  Google Scholar 

  69. Neumann UP, Thelen A, Röcken C, Seehofer D, Bahra M, Riess H, et al. Nonresponse to pre-operative chemotherapy does not preclude long-term survival after liver resection in patients with colorectal liver metastases. Surgery. 2009;146(1):52–9.

    Article  PubMed  Google Scholar 

  70. White RR, Schwartz LH, Munoz JA, Raggio G, Jarnagin WR, Fong Y, et al. Assessing the optimal duration of chemotherapy in patients with colorectal liver metastases. J Surg Oncol. 2008;97(7):601–4.

    Article  PubMed  Google Scholar 

  71. Kishi Y, Zorzi D, Contreras CM, Maru DM, Kopetz S, Ribero D, et al. Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. Ann Surg Oncol. Springer-Verlag; 2010; 17(11):2870–6.

    Google Scholar 

Download references

Compliance with Ethics Guidelines

ᅟ

Conflict of Interest

Sam C. Wang and Michael I. D’Angelica declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY, 10065, USA

    Sam C. Wang & Michael I. D’Angelica

Authors
  1. Sam C. Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael I. D’Angelica
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael I. D’Angelica.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wang, S.C., D’Angelica, M.I. Chemotherapy-Associated Hepatotoxicity and Hepatic Resection for Metastatic Colorectal Cancer. Curr Colorectal Cancer Rep 10, 195–203 (2014). https://doi.org/10.1007/s11888-014-0218-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11888-014-0218-5

Keywords

Search

Navigation